ArticleJournal of dental sciences2026
Phillyrin attenuates high glucose-induced ferroptosis in gingival cells through the activation of 5' adenosine monophosphate-activated protein kinase signaling.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Delayed wound healing in diabetes involves multiple factors, with ferroptosis being one of the key mechanisms. Ferroptosis, marked by iron accumulation and lipid peroxidation, has been implicated in the pathogenesis of various diseases; however, its role in oral wound healing remains unclear. Here, we evaluated its involvement in impaired wound healing, as well as the therapeutic effects of phillyrin, a natural lignan with the potential to ameliorate oxidative stress and diabetic complications. Materials and methods: Smulow-Glickman (S-G) gingival epithelial cells were exposed to high-glucose conditions, followed by treatment with phillyrin. PrestBlue assay and 2 well culture-insert were utilized to assess cell viability and wound healing capacity, respectively. Lipid peroxidation and oxidative stress were determined using commercial assay kits to measure malondialdehyde (MDA) and 8-hydroxy-2-deoxyguanosine (8-OHdG), respectively. Intracellular Fe Results: High glucose, like the ferroptosis inducer erastin, reduced cell viability and wound-healing capacity, whereas ferroptosis inhibitor Ferrostatin-1 or phillyrin treatment conferred comparable protection. Also, we showed that the characteristics of ferroptosis were elevated in high glucose-treated cells, while phillyrin administration reduced these features in a dose-dependent manner. More importantly, we found that this effect may result from phillyrin restoring high-glucose-suppressed 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation, thereby regulating anti-ferroptotic factors and enhancing cellular resilience against ferroptosis. Conclusion: These findings suggest that phillyrin may improve impaired oral wound healing in diabetes through the activation of AMPK and upregulation of anti-ferroptotic mechanisms, underscoring its promise in the treatment of complications associated with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.